Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection

Journal of Clinical Gastroenterology

Volumn 37, Issue 1, 2003, Pages 64-67

  Schmilovitz Weiss, Hemda ^a   Melzer, Ehud ^a   Tur Kaspa, Ran ^a   Ben Ari, Ziv ^a  

^a RABIN MEDICAL CENTER   (Israel)

Author keywords

Hepatitis B; Lamivudine; Renal failure

Indexed keywords

LAMIVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE CLEARANCE; FEMALE; HEMODIALYSIS; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; MALE; OUTCOMES RESEARCH; PATIENT SELECTION; PRIORITY JOURNAL; RECIPIENT; VIRUS INFECTION; VIRUS REPLICATION;

ADULT; HEPATITIS B; HEPATITIS B E ANTIGENS; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; KIDNEY FAILURE, CHRONIC; LAMIVUDINE; MALE; MIDDLE AGED; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037564938     PISSN: 01920790     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004836-200307000-00016     Document Type: Article

References (32)

1. Harnett JD, Zeldis JB, Parfrey PS, et al. Hepatitis B disease in dialysis and transplant patients: Further epidemiologic and serologic studies. Transplantation. 1987;44:369-376.
2. Huang CC, Laim MK, Fong MT. Hepatitis B liver disease in cyclosporine-treated renal allograft recipients. Transplantation. 1990;49:540-544.
3. Parfrey PS, Forbes RDC, Hutchingson A, et al. The impact of renal transplantation on the course of hepatitis B liver disease. Transplantation. 1985;39:610-615.
4. Sengar DPS, Counture RA, Lazarovits AI, et al. Long-term patient and renal allograft survival in HBsAg infection: A recent update. Transplant Proc. 1989;21:3358-3359.
5. Aroldi A, Tarantino A, Montagnino G, et al. Renal transplant recipients and chronic liver disease: Statistical evaluation of predisposing factors. Nephron. 1992;61:290-292.
6. Dhar JM, Al-Khader AA, Al-Sulaiman MH, et al. The significance and implications of hepatitis B infection in renal transplant recipients. Transplant Proc. 1991;23:1785-1786.
7. Dusheiko G, Song E, Bowyer S, et al. Natural history of hepatitis B virus infection in renal transplant recipients: A fifteen year follow-up. Hepatology. 1983;3:330-336.
8. Friedlander MM, Tur-Kaspa R, Rubinger D, et al. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am J Kidney Dis. 1989;14:204-210.
9. Pol S, Debure A, Degott C, et al. Chronic hepatitis in kidney allograft recipients. Lancet. 1990;335:878-880.
10. Grekas D, Dioudis C, Mandraveli K, et al. Renal transplantation in asymptomatic carriers of hepatitis B surface antigen. Nephron. 1995;69:267-272.
11. Perrilo R, Mason AL. Interferon therapy of hepatitis B. Gastroenterol Clin North Am. 1994;23:581-601.
12. Lai KN, Li PKT, Lui SF, et al. Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med. 1991;324:1457-1463.
13. Bang BK, Yang CW, Yoon SA, et al. Prevalence and clinical course of hepatitis B and hepatitis C liver disease in cyclosporine-treated renal allograft recipients. Nephron. 1995;70:397-401.
14. Failrey CK, Mijch A, Gust ID, et al. The increased risk of fatal liver disease in renal transplant patients who are hepatitis Be antigen and/or HBV DNA positive. Transplantation. 1991;52:497-500.
15. Degos F, Lugassy C, Degott C, et al. Hepatitis B virus and hepatitis-B-related viral infection in renal transplant recipients. Gastroenterology. 1988;94:151-156.
16. Agarwal SK, Dash SC, Tiwari SC, et al. Clinicopathological course of hepatitis B infection in surface antigen carriers following living-related renal transplantation. Am J Kidney Dis. 1994;24:78-82.
17. Dienstag JL, Perillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med. 1995;33:1657-1661.
18. Duarte R, Huraib S, Said R, et al. Interferon-alpha facilitates renal transplantation in hemodialysis patients with chronic viral hepatitis. Am J Kidney Dis. 1995;25:40-45.
19. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation. 1996;62:1456-1462.
20. Ben-Ari Z, Broida E, Kittai Y, et al. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol. 2000;95:3579-3582.
21. Knodell RG, Ishak KG, Black WC, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 1981;1:431-435.
22. Tur-Kaspa R, Klein A, Aharonson SH. Hepatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology. 1992;16:1338-1342.
23. Johnson MA, Verpooten GA, Daniel MJ, et al. Single dose pharmacokinetics of lamivudine in subjects with impaired renal function and the effect of hemodialysis. Br J Clin Pharmacol. 1998;46:21-27.
24. Heald AE, Hsyu PH, Yven GJ, et al. Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction. Antimicrob Agents Chemother. 1996;40:1514-1519.
25. Izzedine H, Laynay-Vacher V, Deray G. Dosage of lamivudine in a hemodialysis patient. Nephron. 2000;86:553.
26. Chen RN, Liaw YF, Atkins M. Asian Hepatitis Lamivudine Trial Group. Pretherapy alanine transaminase level as a determinant for hepatitis Be antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Hepatology. 1999;30:770-774.
27. Ysuda K, Okuda K, Endo N, et al. Hypoaminotransferemia in patients undergoing long-term hemodialysis: clinical and biochemical appraisal. Gastroenterology. 1995;109:1295-1300.
28. Fabrizi F, Lunghi G, Finazzi S, et al. Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis. Am J Kidney Dis. 2000;38:1009-1015.
29. Boni C, Bertoletti A, Penna A, et al. Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest. 1998;102:968-975.
30. Lai CL, Chien RN, Leung NWY, et al. A one-year trial of lamivudine for chronic hepatitis B. N Engl J Med. 1998;339:61-68.
31. Honkoop P, Niesters H, de Man M, et al. Lamivudine resistance in immunocompetent chronic hepatitis B. Incidence and patterns. J Hepatol. 1997;26:1393-1395.
32. Fontaine H, Thiers V, Chretin Y, et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000;69:2090-2094.